• Hematology Case Studies With Answers Pdf

These 36 HEMATOGRAPHY Case Studies were added to the Web site between October, 1997 and September, 2000. The cases are factual and reflect medical practice of that time. They have not been embellished or updated in any way. Each case illustrates a different hematologic disorder, and includes.

Abstract

Purpose of review

Although the zebrafish has been established as a research tool over the past 2–3 decades, in hematology it has primarily been used to investigate areas distinct from coagulation. Advantages of this vertebrate model include high fecundity, rapid and external development, and conservation of virtually all clotting factors in the zebrafish genomic sequence. Here we summarize the growing application of this technology to the study of hemostasis and thrombosis.

Recent findings

Loss of function studies have demonstrated conservation of function for a number of zebrafish coagulation factors. These include positive and negative regulators of coagulation, as well as key components of the thrombus itself, such as von Willebrand factor, fibrinogen, and thrombocytes. Such analyses have also been leveraged to aid in the understanding of human variation and disease, as well as perform in vivo structure/function experiments.

Summary

The zebrafish is an organism that lends itself to a number of unique and powerful approaches not possible in mammals. This review demonstrates that there is a high degree of genetic and functional conservation of coagulation, portending future insights into hemostasis and thrombosis through use of this model.

Introduction

The zebrafish (Danio rerio) is a small vertebrate tropical water fish that is now one of several favored systems for the study of human disease, with many unique advantages in comparison to mammalian models[]. Zebrafish possess several characteristics that make it an ideal model to study in the laboratory. Adults are extremely fecund, with the ability to produce 200–300 offspring on a weekly basis. Embryonic development is external and transparent without any requirements for feeding. This accessibility facilitates both simple and complex observations over the first week of life. During the embryonic/larval transition period (0–7 days post fertilization dpf), zebrafish are only millimeters (mm) in length, and hundreds of individuals can be easily maintained in 100 mm culture dishes. Rapid development of all major organ systems initiates during this period, easily observed under low power microscopy. Compared to mammals, a significantly greater number of adults can be bred and maintained in equivalent space.

Genomic conservation of hemostatic factors in zebrafish

Zebrafish share a high degree of genetic conservation with humans, including orthology to 70% of human genes[], although there are slight differences in nomenclature guidelines [3*]. The genome of the zebrafish contains many gene duplications, which has resulted in some neo functionalization and subfunctionalization[]. The majority of coagulation factors appear to be single copy based on genomic sequence[]. It has also been determined that the coagulation cascade is extensively conserved in another teleost fish, Fugurubripes (Fugu, puffer fish), with minimal coagulation factor duplication[–].

Genetic and small molecule screens for hematologic phenotypes in zebrafish

The use of zebrafish in hematology research was pioneered in the mid-1990s, primarily for analysis of hematopoiesis. Large-scale chemical mutagenesis screens employed a forward genetic approach, which led to the identification of many novel molecules regulating hematopoiesis[,]. This technology was later applied to other areas of hematology, and resulted in the discovery of a novel iron exporter, ferroportin[], which was determined to be mutated in autosomal-dominant hemochromatosis[]. The first genetic screen applied to hemostasis utilized laser-induced endothelial injury to induce occlusive thrombi in larvae. Reversal of this phenotype identified a mutant with linkage to the prothrombin(f2) locus[]. Future screens are expected to result in the discovery of novel loci beyond the canonical coagulation cascade.

In addition to genetic screens, zebrafish are particularly suited to phenotype based, large-scale, small molecule screens in embryos and larvae, since these can be arrayed in multi well plates and readily absorb small molecules []. The translational potential of this approach has been demonstrated in hematopoiesis. A stable derivative of prostaglandin E₂(PGE₂) was identified as a hematopoietic stem cell regulator in zebrafish embryos, followed by confirmation using competitive transplantation in mice [] and nonhuman primates []. This culminated in a successful phase I trial for ex vivo treatment of umbilical cord stem cells with PGE₂ prior to transplantation, which demonstrated clear safety as well as encouraging therapeutic potential[]. Given the data that show conservation of hemostatic pathways at both genetic and functional (see below) levels, there is similar potential to isolate novel regulators of hemostasis using zebrafish.

Analysis of coagulation factors in zebrafish demonstrates conservation of structure and function

Examination of specific zebrafish coagulation factors has demonstrated conservation with mammals at multiple levels. Until the relatively recent application of genome editing nucleases to gene targeting in zebrafish[–], the vast majority of loss of function analyses were by knockdown using antisense morpholino oligonucleotides (MOs)[]. Targeting of F2 using MOs demonstrated a bimodal phenotype [] which bore a partial resemblance to the knockout of F2 in mice [,]. Severe reduction resulted in morphological defects. These included retarded growth, brain and tail bud abnormalities at 1 dpf, followed by absence of circulating blood cells, reduced blood flow, pericardial edema, and truncal hemorrhage by 2 dpf. A subset of embryos did not exhibit morphologic defects, and intracranial hemorrhage was observed in 5–10% of this group. Acoagulopathic phenotype was detected through prolongation of the time to occlusion after laser-induced endothelial injury, and this was rescued by infusion of recombinant zebrafish F2.

Zebrafish factor VII (F7) was found to have a high degree of similarity with mammalian F7, and protein was detected in blood and liver []. As expected, F7 depleted plasma displayed a significant delay in fibrin generation. MO knockdown of F7 prolonged the laser injury induced time to occlusion in zebrafish larvae, consistent with a bleeding phenotype []. Recent experiments have called into question whether the mammalian F7 activating protease (Fsap/habp2) truly activates F7 []. In support of these data, MO knockdown of Fsap in larvae did not affect either the ability to form a thrombus in response to endothelial injury or activation of F7 []. In contrast, hepsin knockdown decreased F7 activation and inhibited induced thrombus formation [], results that are inconsistent with the mouse knockout [].

Conservation of structure and function of the adhesive coagulation factors, von Willebrand factor (Vwf)and fibrinogen, has been demonstrated in zebrafish. Like humans, the zebrafish vwf locus consists of 52 exons, although it spans only 81kilobases (kb) as opposed to 176 kb in humans [,]. Cloning of the cDNA demonstrated conservation of sequences required for propeptide and ADAMTS13 cleavage, and individual domain structures were conserved with 46% overall protein identity []. Expressed zebrafish vwf cDNA formed high molecular weight multimers and pseudo-Weibel-Palade bodies in cell culture[]. Antisense knockdown mediated by MOs resulted in hemorrhage and loss of thrombocyte aggregation []. Taken together, these data demonstrate conservation of the key functions of VWF.

Fibrinogen is a hexameric protein formed as a homodimer of three polypeptide chains, and is encoded by the three loci, FGA, FGB, and FGG, which reside in a cluster on the long arm of human chromosome 4. The existence of three syntenic orthologs (fga, fgb, and fgg) to human fibrinogen was recognized through genomic sequencing[] and confirmed by cytogenetic in situ hybridization []. The predicted amino acid sequences of zebrafish Fgb and Fgg share more than 50% identity with their human orthologs, while Fga is less well conserved []. In the case of the fibrinogen chains, mRNA in situ hybridization demonstrated conserved expression in liver, but also early expression in the yolk sac syncytial layer[,]. Expression of an Fgb-GFP (green fluorescent protein) fusion demonstrated incorporation into a developing induced thrombus in larvae. MO knockdown of the three fibrinogen chains demonstrated intracranial and intramuscular hemorrhage, consistent with symptoms of human hypo- and a fibrinogenemia, while single deficiencies were less penetrant []. Although ablation of single chains in mice and humans completely eliminated fibrinogen production[,], MOs do not wholly eradicate target mRNA, a known shortcoming of this technology. Instead a complete knockout of fga was achieved using genome editing zinc finger nucleases (ZFNs), and resulted in overt hemorrhage in adult homozygous mutant fish []. Variable lethality was observed in fga^−/− mutants, which is not surprising given the known heterozygosity of laboratory zebrafish [,]. This is consistent with the mouse Fga knockout, for which the genetic background altered survival [].

The natural anticoagulant factors are conserved in zebrafish genomic sequence, including antithrombin III (at3)[,]. Targeted mutagenesis of at3 using ZFNs resulted in adult lethality secondary to massive intracardiac thrombosis []. While lethality was expected based on data from the mouse knockout [] and clinical observations [42], this was in contrast to mammalian in utero lethality. Induction of thrombus formation by laser injury in 3 dpf larvae identified an unexpected prolongation of the time to occlusion, a bleeding phenotype. This was rescued by injection of human fibrinogen, consistent with a consumptive coagulopathy. Injection of fluorescently tagged human fibrinogen into larvae demonstrated disseminated intravascular coagulation with widespread fibrin clots. It was surprising that juvenile fish could tolerate what is a severe coagulation defect in mammals, suggesting the potential for species specific protective factors against this potent insult. The coagulopathy was also rescued by injection of plasmids expressing human AT3, and this was utilized as an in vivo platform to evaluate known AT3 mutations. As expected, mutations in the P1 arginine abolished the ability to rescue, but surprisingly loss of the heparin binding site had no effect and was phenotypically normal. This demonstrates the value of this system for in vivo assessment of coagulation factor defects.

Thrombocytes: nucleated platelets

One specific area of interest has been the thrombocyte, with conservation of a number of platelet functions and regulatory processes. Unlike mammalian platelets, fish thrombocytes are nucleated []. Early work in trout demonstrated thrombocyte aggregation in response to thrombin and a thromboxane mimetic, U-46619, but not other eicosanoids []. The existence of an integrin-like fibrinogen receptor was revealed when it was shown that the tetrapeptide RGDS inhibited thrombocyte aggregation []. Ultrastructure analysis has verified that thrombocytes contain vesicles similar to the mammalian open canalicular system[]. Despite the lack of a polyploid megakaryocyte-like stage in zebrafish, thrombopoietin (Tpo) and its receptor (Mpl) are conserved, and knockdown of the latter results in decreased circulating thrombocytes []. Zebrafish thrombocytes aggregate in response to platelet agonists (collagen, ADP, ristocetin, and arachidonic acid) and many receptors are conserved (ADP, collagen, VWF and thromboxane)[]. Studies utilizing zebrafish thrombocyte shave led to novel insights into platelet function and have been reviewed elsewhere[,].

Dissection of human coagulation and associated disorders using zebrafish

Coagulation is a multifaceted process, requiring contributions from cellular, vascular, and plasma protein elements. As demonstrated for At3, zebrafish present the opportunity to rapidly screen novel human sequence variants in such an in vivo context. This has been leveraged as an adjunct technique for positional cloning of factors affecting human platelets and their associated disorders. The first disease examined was human familial autosomal dominant thrombocytopenia. After localization of a locus on human chromosome 10p, the microtubule-associated serine/threonine-like kinase (MASTL) gene was identified as a candidate. Knockdown of the zebrafish ortholog with MOs resulted in reduction of circulating thrombocytes, as well as decreased expression of itga2b and mpl, providing supportive evidence []. MO knockdown in zebrafish also reinforced the discoveries of NBEAL2 and RBM8A as the affected genes in the gray platelet and thrombocytopenia with absent radii syndromes, respectively [,].

Induced thrombosis in larval zebrafish has been used as a method to confirm targets identified through a systems biology approach. In one study, candidates were selected by virtue of megakaryocyte expression as compared to other hematopoietic lineages, sorted for those with transmembrane domains, with endothelial expression as a final selective criterion[]. These putative novel platelet membrane proteins underwent functional screening in vivo by induction of arterial thrombosis following MO knockdown. Four novel genes (two that promoted thrombus formation, BAMBI and LRRC32, and two inhibitory, ESAM and DCBLD2) were discovered[]. A similar approach used genome-wide platelet mRNA expression profiling in conjunction with association studies to detect potential targets. This was followed by induced thrombosis in zebrafish larvae, and identified COMMD7 and LRRFIP1 as potential enhancers of thrombus formation[]. Gene silencing in zebrafish has also validated hits localized through meta-analyses of genome-wide association studies for platelet count and mean platelet volume[]. MO knockdown in larvae confirmed 5 genes that regulated thrombopoiesis and/or erythropoiesis.

Conclusion

The zebrafish is a well-established vertebrate model organism with a number of unique and powerful advantages that make it a useful emerging tool for studying hemostasis. Studies to date have conclusively demonstrated significant homology with mammals. Functional conservation has been established for F2, F7, Vwf, fibrinogen, and Mpl, although there have been some unexpected differences in other factors. Knockdown of hepsin indicated a role in the initiation of coagulation by activation of F7, in contrast to studies in mice. At3 demonstrated that overall the effects of loss of function were conserved with mammals, but the temporal difference in phenotypic expression suggests that there is the potential to uncover novel biology.

The hemostatic system in zebrafish provides an opportunity to perform moderate to high throughput experiments in an intact organism, an advantage over in vitro or ex vivo systems. Traditional aspects of zebrafish investigation include genetic screens for modifier genes and evaluation of small molecules for novel therapeutics[]. These have been highly successful for other disciplines, including hematopoiesis, cardiology, and oncology [], although it remains to be seen if this will be successful in hemostasis. In combination with standard knockdown and emerging genome editing approaches, zebrafish are exquisitely poised to filter systems biology pipelines, confirm candidate disease genes in positional cloning, and perform in vivo structure/function analyses for verification of human mutations or predictions from in vitro studies. These will enable further dissection of hemostasis, thrombosis, and platelet disorders with a throughput not available in larger animal models.

​

• Zebrafish coagulation factors demonstrate structural and functional homology with their mammalian orthologs

• The initiation and endpoints of coagulation are conserved in zebrafish.

• Zebrafish present a unique and powerful system for the identification of novel therapeutics for hematologic disorders.

• Genome editing technology allows for rapid in vivo validation of coagulation factor structure/function in zebrafish.

• Putative human disease-causing variants can be rapidly confirmed in zebrafish

Acknowledgments

The authors thank Dr. Colin Kretz for critical reading of the manuscript. This work was supported in part by American Heart Association #0675025N, NICHD HD028820, the Bayer Hemophilia Awards Program, and the National Hemophilia Foundation/Novo Nordisk Career Development Award (J.A.S.). J.A.S. is the Diane and Larry Johnson Family Scholar of Pediatrics and Communicable Diseases.

Footnotes

Conflicts of interest

There are no conflicts of interest.

References

Hematology Case Studies With Answers Pdf

Description

Hematology and Coagulation is a clear and easy-to-read presentation of core topics and detailed case studies that illustrate the application of hematopathology knowledge to everyday patient care. In order to be successful, as well as to pass the American Board of Pathology examination, all pathology residents must have a good command of hematopathology, including the challenging topics of hematology and coagulation. Hematology and Coagulation meets this challenge head on.

This basic primer offers practical examples of how things function in the hematopathology clinic as well as useful lists, sample questions, and a bullet-point format ideal for quick pre-board review. This book provides only the most clinically relevant examples designed to educate senior medical students, residents and fellows and 'refresh' the knowledge base, without overwhelming students, residents, and clinicians.

• Takes a practical and easy-to-read approach to understanding hematology and coagulation at an appropriate level for both board preparation as well as a professional refresher course
• Covers all important clinical information found in larger textbooks in a more succinct and easy-to-understand manner
• Covers essential concepts in hematopathology in such a way that fellows and clinicians understand the methods without having to become specialists in the field

Readership

Residents and fellows in pathology and clinical chemistry, practicing pathologists and clinical chemists

• Dedication
• Preface
• Chapter 1. Complete Blood Count and Peripheral Smear Examination
  • 1.1 Introduction
  • 1.2 Analysis of Various Parameters by Hematology Analyzers
  • 1.3 Review of Peripheral Smear
  • 1.4 Special Situations with CBC and Peripheral Smear Examination
  • Key Points
  • References
• Chapter 2. Bone Marrow Examination and Interpretation
  • 2.1 Introduction
  • 2.2 Fundamentals of Bone Marrow Examination
  • 2.3 Bone Marrow Examination Findings and Bone Marrow Failure
  • Key Points
  • References
• Chapter 3. Red Blood Cell Disorders
  • 3.1 Introduction
  • 3.2 Anemia: Morphological and Etiological Classification
  • 3.3 Common Causes of Anemia
  • 3.4 Hemolytic Anemia
  • 3.5 Red Cell Poikilocytosis
  • 3.6 Red Cell Inclusions
  • Key Points
  • References
• Chapter 4. Hemoglobinopathies and Thalassemias
  • 4.1 Introduction
  • 4.2 Hemoglobin Structure and Synthesis
  • 4.3 Introduction to Hemoglobinopathies
  • 4.4 Other Hemoglobin Variants
  • 4.5 Laboratory Investigation of Hemoglobinopathies
  • 4.6 Diagnostic Tips for Thalassemias, Sickle Cell Disease, and Other Hemoglobinopathy
  • 4.7 Apparent Hemoglobinopathy After Blood Transfusion
  • Key Points
  • References
• Chapter 5. Benign White Blood Cell and Platelet Disorders
  • 5.1 Introduction
  • 5.2 Hereditary Variation in White Blood Cell Morphology
  • 5.3 Changes in White Cell Counts
  • 5.4 Platelet Disorders
  • Key Points
  • References
• Chapter 6. Myeloid Neoplasms
  • 6.1 Introduction
  • 6.2 Classification of Myeloid Neoplasm
  • 6.3 Myeloproliferative Neoplasm
  • 6.4 Myeloid and Lymphoid Neoplasm Associated with Eosinophilia
  • 6.5 Myelodysplastic/Myeloproliferative Neoplasms
  • 6.6 Myelodysplastic Syndrome
  • 6.7 Acute Leukemia
  • Key Points
  • References
• Chapter 7. Monoclonal Gammopathy and Its Detection
  • 7.1 Introduction
  • 7.2 Diagnostic Approach to Monoclonal Gammopathy Using Electrophoresis
  • 7.3 Plasma Cell Neoplasm
  • 7.4 Cytogenetics in Myeloma Diagnosis
  • Key Points
  • References
• Chapter 8. Application of Flow Cytometry in the Diagnosis of Hematological Disorders
  • 8.1 Introduction
  • 8.2 Flow Cytometry and Mature B Cell Lymphoid Neoplasms
  • 8.3 Flow Cytometry and Mature T and Natural Killer Cell Lymphoid Neoplasms
  • 8.4 Plasma Cell Dyscrasias
  • 8.5 Flow Cytometry and Acute Leukemia
  • 8.6 Flow Cytometry and Myelodysplastic Syndrome
  • 8.7 Flow Cytometry and Hematogones
  • Key Points
  • References
• Chapter 9. Cytogenetic Abnormalities and Hematologic Neoplasms
  • 9.1 Introduction
  • 9.2 Cytogenetic Abnormalities in Chronic Myeloid Leukemia
  • 9.3 Cytogenetic Abnormalities in Myelodysplastic Syndrome
  • 9.4 Cytogenetic Abnormalities in Patients with Acute Myeloid Leukemia
  • 9.5 Cytogenetic Abnormalities in Actute Lymphoblastic Leukemia
  • 9.6 Cytogenetic Abnormalities in Multiple Myeloma
  • 9.7 Cytogenetic Abnormalities in B and T Cell Lymphomas
  • Key Points
  • References
• Chapter 10. Benign Lymph Nodes
  • 10.1 Introduction
  • 10.2 Reactive Lymphoid States
  • 10.3 Specific Clinical Entities with Lymphadenopathy
  • Key Points
  • References
• Chapter 11. B Cell Lymphomas
  • 11.1 Introduction
  • 11.2 Follicular Lymphoma
  • 11.3 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • 11.4 B Cell Prolymphocytic Leukemia
  • 11.5 Mantle Cell Lymphoma
  • 11.6 Marginal Zone B Cell Lymphoma
  • 11.7 Burkitt Lymphoma
  • 11.8 Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • 11.9 Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
  • 11.10 Diffuse Large B Cell Lymphoma
  • 11.11 Hairy Cell Leukemia
  • Key Points
  • References
• Chapter 12. T Cell and Natural Killer Cell Lymphomas
  • 12.1 Introduction
  • 12.2 Nodal T Cell Lymphomas
  • 12.3 Extranodal NK/T Cell Lymphomas
  • 12.4 Cutaneous T Cell Lymphoma
  • 12.5 Leukemia/disseminated
  • Key Points
  • References
• Chapter 13. Hodgkin Lymphoma
  • 13.1 Introduction
  • 13.2 Overview of Hodgkin Lymphoma
  • 13.3 Classification of Hodgkin Lymphoma
  • 13.4 Immunostains for Diagnosis of Hodgkin Lymphoma
  • 13.5 Staging of Hodgkin Lymphoma
  • Key Points
  • References
• Chapter 14. Lymphoproliferative Disorders Associated with Immune Deficiencies and Histiocytic and Dendritic Cell Neoplasms
  • 14.1 Introduction
  • 14.2 Lymphoproliferative Disorders Associated with Immune Deficiency
  • 14.3 Histiocytic and Dendritic Cell Neoplasms
  • Key Points
  • References
• Chapter 15. Essentials of Coagulation
  • 15.1 Introduction
  • 15.2 Normal Hemostasis
  • 15.3 Thrombocytopenia and Thrombocytopathia
  • 15.4 Tests for Platelet Function
  • 15.5 Secondary Hemostasis
  • 15.6 Tests for Secondary Hemostasis
  • 15.7 Antiplatelets and Anticoagulants
  • Key Points
  • References
• Chapter 16. Thrombophilias and Their Detection
  • 16.1 Introduction
  • 16.2 Thrombophilia: Inherited Versus Acquired
  • 16.3 Factor V Leiden
  • 16.4 Prothrombin Gene Mutation
  • 16.5 Protein C Deficiency
  • 16.6 Protein S Deficiency
  • 16.7 Antithrombin III Deficiency
  • 16.8 Hyperhomocysteinemia
  • 16.9 Increased Factor VIII Activity
  • 16.10 Acquired Causes of Thrombophilia
  • Key Points
  • References
• Chapter 17. Sources of Errors in Hematology and Coagulation
  • 17.1 Introduction
  • 17.2 Errors in Routine Hematology Testing
  • 17.3 Errors in Specific Hematology Testing
  • 17.4 Errors in Coagulation Testing
  • Key Points
  • References
• Index

Details

Amer Wahed

Amer Wahed is a graduate of Medicine, training initially in Internal Medicine at Royal Postgraduate Medical School, London, England. He subsequently trained in Anatomic and Clinical Pathology from the University of Texas-Houston Medical School. After working for several years in a private setting, he joined the Department of Pathology and Laboratory Medicine at the University of Texas-Houston Health Sciences Center. Currently he is an Assistant Professor of Pathology and Laboratory Medicine and Associate Director of Clinical Chemistry and Immunology at Memorial-Hermann Hospital at the Texas Medical Center. He is also the Associate Director of the Pathology Residency Program at the University of Texas-Houston Medical School. Dr. Wahed has a strong interest in teaching and is actively involved in the education of medical students, graduate students, residents, and fellows. He has been recognized for his teaching contributions through awards from his department, as well as the Office of the Dean. He is also active in mentoring pathology residents in research and has published multiple papers in peer-reviewed journals.

Associate Professor of Pathology and Laboratory Medicine, University of Texas, McGovern School of Medicine, Houston, TX, USA

Amitava Dasgupta

Amitava Dasgupta received his PhD degree in Chemistry from Stanford University and his fellowship training in Clinical Chemistry from the Laboratory Medicine Department of the University of Washington School of Medicine at Seattle. He is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Texas Health Sciences Center located at the Texas Medical Center at Houston. Dr. Dasgupta has published 210 scientific papers, written many invited review articles, and has edited, co-edited or written 15 books. He is on the Editorial Board of five major medical journals including American Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, Therapeutic Drug Monitoring, Clinica Chimica Acta and Journal of Clinical Laboratory Analysis.

Professor, Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas, Houston, TX, USA

Reviews

'It would be of interest to any pathologist or laboratory medicine practitioner in practice wanting a quick review of the subject…a great book to review in preparation for the clinical pathology board exam. Score: 86 - 3 Stars' --Doody's

Automation studio 64 bits download failed. Automation Studio 6 ProfessionalThe only thing you have to do it yourself is download Automation Studio 6 Professional, run it and intall the software.Automation Studio 6 ProfessionalAfter installing the Software, copy the crack from the Crack folder and paste it to the folder installation.

'At A Glance Hematology and Coagulation is a clear and easy-to-read presentation of core topics and detailed case studies that illustrate the application of hematopathology knowledge to everyday patient care. In order to be successful, as well as to pass the American Board of Pathology examination, all pathology residents must have a good command of hematopathology, including the challenging topics of hematology and coagulation. Hematology and Coagulation meets this challenge head on. This basic primer offers practical examples of how things function in the hematopathology clinic as well as useful lists, sample questions, and a bulletpoint format ideal for quick preboard review. This book provides only the most clinically relevant examples designed to educate senior medical students, residents and fellows and 'refresh' the knowledge base, without overwhelming students, residents, and clinicians.

Description: This is a review of clinical hematology and coagulation concepts, principles, and practices that are assessed in the clinical pathology board exam.

Purpose: The purpose is to provide a 'strong foundation for students, residents and fellows embarking on the journey of mastering hematology' and to be a reference for preparation for the exam.

Audience: This book was written for 'students, residents and fellows.' It would be of interest to any pathologist or laboratory medicine practitioner in practice wanting a quick review of the subject. It may be of interest to other medical practitioners who want to gain some insight into contemporary hematology and coagulation testing (e.g., primary care physicians, specialists, etc.). The first author is relatively new to this field, but the senior author is widely published and internationally respected in the fields of clinical chemistry and toxicology.

Features: The 17 chapters cover most aspects of laboratory hematology, hematopathology, and coagulation. Each chapter follows a standard format of an introduction, explanation of standard tests/interpretations/processes, ending with a bulleted list of key points. This is a pretty comprehensive book, written in a no-frills, concise manner. I agree with the authors if the reader knows the majority of the material in this book, s/he is ready for the American Board of Pathology exam. There are no photomicrographs and only one flow cytometry figure in the book, instead readers are referred to online image banks for examples. Chapter 17, which discusses sources of error in hematology and coagulation, is relatively unique and enlightening. Experienced hematology laboratory directors would find this chapter useful.

Assessment: This is a great book to review in preparation for the clinical pathology board exam.' --Valerie Ng, PhD MD (Alameda County Medical Center/Highland Hospital)

Hematology and Coagulation is a clear and easy-to-read presentation of core topics and detailed case studies that illustrate the application of hematopathology knowledge to everyday patient care. In order to be successful, as well as to pass the American Board of Pathology examination, all pathology residents must have a good command of hematopathology, including the challenging topics of hematology and coagulation. Hematology and Coagulation meets this challenge head on.

This basic primer offers practical examples of how things function in the hematopathology clinic as well as useful lists, sample questions, and a bullet-point format ideal for quick pre-board review. This book provides only the most clinically relevant examples designed to educate senior medical students, residents and fellows and 'refresh' the knowledge base, without overwhelming students, residents, and clinicians.

'>